1082745-53-6

Basic information

• Product Name: 5-aMino-1-(4,4-difluorocyclohexyl)-1H-pyrazole-4-carbonitrile
• Synonyms: 5-aMino-1-(4,4-difluorocyclohexyl)-1H-pyrazole-4-carbonitrile
• CAS NO: 1082745-53-6
• Molecular Formula: C10H12F2N4
• Molecular Weight: 226.229
• EINECS: -0
• Mol File: 1082745-53-6.mol

Chemical Properties

• CAS DataBase Reference: 5-aMino-1-(4,4-difluorocyclohexyl)-1H-pyrazole-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 5-aMino-1-(4,4-difluorocyclohexyl)-1H-pyrazole-4-carbonitrile(1082745-53-6)
• EPA Substance Registry System: 5-aMino-1-(4,4-difluorocyclohexyl)-1H-pyrazole-4-carbonitrile(1082745-53-6)

Safety Data

• Hazardous Substances Data: 1082745-53-6(Hazardous Substances Data)

Upstream product

• 123-06-8 Ethoxymethylenemalononitrile 
• 22515-18-0 4,4-difluorocyclohexanone 
• 1214910-81-2 C₂HF₃O₂*C₆H₁₂F₂N₂ 
• 1214910-72-1 N'-(4,4-difluorocyclohexyl)hydrazinecarboxylic acid tert-butyl ester 

Downstream Products

• 1082745-54-7 5-amino-1-(4,4-difluoro-cyclohexyl)-1H-pyrazole-4-carboxylic acid amide 
• 1214911-72-4 C₁₈H₁₉F₂N₅O₄ 
• 1214911-74-6 C₁₈H₁₇F₂N₅O₃ 
• 1214908-07-2 C₁₇H₁₇F₂N₅O 
• 1214909-62-2 C₂₅H₃₁F₂N₅O₂ 
• 1214910-10-7 C₁₈H₁₉F₂N₅O₂ 
• 1214910-24-3 C₁₈H₁₉F₂N₅O*ClH 
• 1214910-26-5 C₂₀H₁₉F₂N₇O 

Relevant articles and documents

PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE DERIVATIVES AS PDE9 INHIBITORS

A compound of the general formula (I) wherein R1 is selected from the group consisting of phenyl unsubstituted or substituted with 1 to 3 substituents selected from F, Cl, Br, I, CN, -O-C1-C3-alkyl, fluorinated -O-C1-C3-alkyl, -(CH2)mOH and 5-membered heterocyclic group with 1 or 2 heteroatoms selected from N, O and S; and 6- or 10-membered heteroaryl with 1 to 3 heteroatoms selected from O, N and S; R2 and R3 independently of each other represent H atom or straight or branched C1-C3 alkyl; R4 is selected from the group consisting of 4- to 6- membered cycloalkyl, wherein one of carbon atoms can be replaced by O atom, and which is unsubstituted or substituted with one or two halogen atoms,and straight or branched C1-C4 alkyl; Q represents a bond or C1-C3-alkylene, which can be optionally substituted by one to three C1-C3-alkyls; X is selected from the group consisting of O, NR5, and S(O)p; R5 represents H atom or C1-C3alkyl; m is 1, 2 or 3; p is 0, 1 or 2; and salts thereof, for use as a medicament, in particular for treating cognitive function disorders and neurodegenerative diseases.

COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS

The invention relates to novel cycloalkyl- or cycloalkenyl-substituted pyrazolopyrimidinones of formula (I), wherein ā is selected from the group A1 consisting of a C3-C8-cycloalkyl group or a C4-C8-cycloalkenyl group, whereby the members of C3-C8-cycloalkyl group being selected from the group of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl and cyclooctanyl; and the members of the C4-C8-cycloalkenyl group, being selected from cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclopentadienyl, cyclohexadienyl, cycloheptadienyl, cyclooctadienyl, cycloheptatrienyl, cyclooctathenyl, cyclooctatetraenyl. The new compounds shall be used for the manufacture of medicaments, in particular medicaments for improving perception, concentration, learning and/or memory in patients in need thereof. Chemically, the compounds are characterised as pyrazolopyrimidinones with a cycloalkyl-moiety directly bound to the 1 position of the pyrazolopyrimidinone and a second substituent in the 6 position which is bound via an optionally substituted methylene-bridge. Further aspects of the present invention refer to a process for the manufacture of the compounds and their use for producing medicaments.

NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDER

The invention relates to novel pyrazolopyrimidinones according to formula (I). The new compounds shall be used for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease. Further aspects of the present invention refer to a process for the manufacture of the compounds and their use for producing medicaments.

NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS

The invention relates to novel pyrazolopyrimidinones according to formula (I). The new compounds shall be used for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease. Further aspects of the present invention refer to a process for the manufacture of the compounds and their use for producing medicaments.

AMINO-HETEROCYCLIC COMPOUNDS

The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing the compounds of Formul

AMINO-HETEROCYCLIC COMPOUNDS

The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing the compounds of Formul